Original research, market analyses, and in-depth reports on the trends, policies, and pipelines shaping the future of pharmaceutical and life sciences in Canada.
Canada’s pharmaceutical landscape moves fast. Drug approvals, biosimilar switches, pricing negotiations, and R&D investments — the decisions shaping the industry happen daily. The Pharma Canada Reports exist to give executives, regulators, and researchers the structured, evidence-based intelligence they need to stay ahead.
From monthly approval trackers to annual market analyses, our reports cut through the noise and deliver what matters most to Canada’s pharma community.
Report Categories
Regulatory & Policy Reports
Tracking Health Canada’s evolving regulatory framework — from drug submission timelines to policy reforms that affect how medicines reach Canadian patients. Essential reading for regulatory affairs teams and policy professionals.
Drug Pipeline & Approvals
A running record of every drug under review, newly approved, or withdrawn in Canada. Updated monthly, this is the go-to resource for market watchers, commercial teams, and investor relations professionals.
Market Access & Pricing
Canada’s reimbursement environment is one of the most complex in the world. Our market access reports analyse CADTH and INESSS recommendations, pan-Canadian pricing negotiations, and formulary listing decisions across provinces.
R&D & Clinical Trials
From Phase I to commercialisation, we track the clinical pipeline being developed in and for the Canadian market — covering academic institutions, biotech startups, and multinational sponsors.
Biosimilars & Generics
With provincial biosimilar switching policies still evolving, our biosimilars reports provide the clearest picture of uptake rates, payer mandates, and what the competitive landscape looks like province by province.
Featured Reports
Canada’s Biosimilar Uptake — Progress, Gaps & What Comes Next
Canada was among the first countries to introduce biosimilar switching policies, yet uptake remains uneven across provinces. British Columbia and Alberta have led the way with mandatory switch programmes, while others continue to lag. This special report examines why the gap exists, what it means for patients and payers, and what policy levers could accelerate adoption nationally.
